Omnicell (NASDAQ:OMCL - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, July 31st. Analysts expect the company to announce earnings of $0.30 per share and revenue of $275.57 million for the quarter. Omnicell has set its Q2 2025 guidance at 0.190-0.320 EPS.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. The firm had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The business's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.03 EPS. On average, analysts expect Omnicell to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Omnicell Price Performance
Shares of NASDAQ:OMCL traded up $0.14 during trading on Friday, reaching $28.27. The company had a trading volume of 428,411 shares, compared to its average volume of 432,199. The company has a fifty day moving average of $29.11 and a two-hundred day moving average of $33.62. The stock has a market capitalization of $1.32 billion, a P/E ratio of 61.46, a price-to-earnings-growth ratio of 8.21 and a beta of 0.76. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.74. The company has a current ratio of 1.38, a quick ratio of 1.23 and a debt-to-equity ratio of 0.13.
Institutional Investors Weigh In On Omnicell
A number of large investors have recently added to or reduced their stakes in OMCL. Jane Street Group LLC lifted its position in shares of Omnicell by 201.5% in the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company's stock worth $5,722,000 after purchasing an additional 109,382 shares during the period. AQR Capital Management LLC lifted its position in shares of Omnicell by 42.1% in the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company's stock worth $627,000 after purchasing an additional 5,311 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Omnicell by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company's stock worth $4,337,000 after purchasing an additional 4,866 shares during the period. Finally, Empowered Funds LLC lifted its position in shares of Omnicell by 14.3% in the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company's stock worth $348,000 after purchasing an additional 1,243 shares during the period. Institutional investors own 97.70% of the company's stock.
Analyst Ratings Changes
A number of equities analysts have recently commented on OMCL shares. Benchmark decreased their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Bank of America lifted their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Wall Street Zen upgraded shares of Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 12th. Wells Fargo & Company lifted their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday, July 21st. Finally, Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $45.33.
View Our Latest Analysis on Omnicell
About Omnicell
(
Get Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Further Reading
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
